Eli Lilly and Company (NYSE: LLY) has initiated a Phase I clinical trial of LY4336619, a first‑in‑class ALPPL2/CD3 bispecific antibody and T‑cell engager (TCE), for the treatment of advanced solid tumors. The program is intended for solid tumors such as ovarian cancer and endometrial cancer, and the drug has demonstrated superior antitumor efficacy when combined with an FRα ADC.
Trial Milestone
| Item | Detail |
|---|---|
| Sponsor | Eli Lilly and Company (NYSE: LLY) |
| Asset | LY4336619 (investigational) |
| Modality | First‑in‑class ALPPL2/CD3 bispecific antibody – T‑cell engager (TCE) |
| Phase | Phase I – first‑in‑human |
| Population | Patients with advanced solid tumors (planned target: ovarian and endometrial cancer) |
| Planned Enrollment | 370 patients |
| Initiation Date | 10 Nov 2026 |
| Expected Completion | March 2032 |
Drug Profile & Mechanism of Action
- Molecule: LY4336619, described as first‑in‑class, indicating no directly comparable ALPPL2/CD3 bispecific is currently in clinical development.
- Dual‑Target Design: One arm binds ALPPL2, a tumor‑associated antigen, while the other engages CD3 on T cells – the classic bispecific T‑cell engager architecture that redirects cytotoxic T cells to kill ALPPL2‑expressing tumor cells.
- Combination Strategy: Demonstrated superior antitumor efficacy when combined with an FRα ADC (folate receptor alpha antibody–drug conjugate), supporting a two‑modality attack on solid tumors; the specific ADC partner and preclinical data were not disclosed.
- Indication Focus: Development is aimed at gynecologic solid tumors, including ovarian and endometrial cancer – disease areas with high unmet need in advanced settings.
Clinical Evidence – Phase I Trial
| Item | Detail |
|---|---|
| Design | Phase I, first‑in‑human study |
| Planned Sample Size | 370 patients with solid tumors |
| Primary Objectives | Not disclosed (Phase I typically assesses safety, tolerability, PK/PD) |
| Timeline | Initiated Nov 2026; expected completion March 2032 |
| Interim Data | Data not yet disclosed |
The unusually large planned enrollment of 370 patients for a Phase I trial suggests a multi‑stage program – likely encompassing dose escalation followed by sizable expansion cohorts – and an extended development horizon running through March 2032.
Market Impact & Outlook
- Oncology Portfolio Depth: The trial adds an immuno‑oncology bispecific to Eli Lilly’s rapidly expanding oncology pipeline, complementing the company’s investments in targeted and antibody–drug conjugate modalities.
- TCE Modality Momentum: T‑cell engagers have reshaped hematologic oncology; extending the approach to solid tumors via ALPPL2 targeting represents one of the field’s key frontier bets.
- Combination‑Driven Differentiation: Pairing a TCE with an FRα ADC could offer a rationale for improved efficacy in gynecologic tumors, where FRα is frequently overexpressed – though clinical validation remains ahead.
- Long Development Runway: With completion expected in 2032, near‑term milestones will center on initial safety, tolerability, and early efficacy signals from the Phase I program.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the clinical development of LY4336619, including trial timelines, enrollment, safety and efficacy outcomes, and potential future indications. Actual results may differ materially due to risks including dose‑limiting toxicities, inadequate antitumor activity, combination‑partner dynamics, regulatory decisions, and competitive developments in the immuno‑oncology landscape.-Fineline Info & Tech
